Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug;25(8):e352-e362.
doi: 10.1016/S1470-2045(24)00075-5.

Radiotherapy, immunity, and immune checkpoint inhibitors

Affiliations
Review

Radiotherapy, immunity, and immune checkpoint inhibitors

Connor Lynch et al. Lancet Oncol. 2024 Aug.

Abstract

Radiotherapy exerts immunostimulatory and immunosuppressive effects, both locally, within the irradiated tumour microenvironment, and systemically, outside the radiation field. Inspired by preclinical data that showed synergy between radiotherapy and immune checkpoint inhibitors, multiple clinical trials were initiated with the hypothesis that combined treatment with radiotherapy and immune checkpoint inhibitors could stimulate a robust systemic immune response and improve clinical outcomes. However, despite early optimism, radioimmunotherapy trials in the curative and metastatic settings have met with little success. In this Review, we summarise the immunostimulatory effects of radiotherapy that provided the theoretical basis for trials of combination radiotherapy and immune checkpoint inhibitors. We also discuss findings from clinical trials incorporating radiotherapy and immune checkpoint inhibitors and examine the success of these trials in the context of the immunosuppressive effects of radiotherapy. We conclude by highlighting targets for relieving radiotherapy-induced immunosuppression with the goal of enhancing the combined effects of radiotherapy and immune checkpoint inhibitors.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests SPP reports a patent pending for personalising treatment approaches for patients receiving immunotherapy and is a cofounder of PersonaDx. RRW reports stock and other ownership interests with Boost Therapeutics, Immvira, Reflexion Pharmaceuticals, Coordination Pharmaceuticals, Magi Therapeutics, and Oncosenescence; ownership interest in PersonaDx as a cofounder; consulting or advisory fees from Aettis, AstraZeneca, Coordination Pharmaceuticals, Genus, Merck Serono, Nano proteagen, NKMax America, and Shuttle Pharmaceuticals; research grant funding from Varian and Regeneron; a patent pending for “Methods and kits for diagnosis and triage of patients with colorectal liver metastases”; a provisional patent for “Molecular subtyping of colorectal liver metastases to personalize treatment approaches”; and compensation for travel, accommodations, or expense reimbursement from AstraZeneca, Boehringer Ingelheim, and Merck Serono. CL declares no competing interests.

MeSH terms

Substances

LinkOut - more resources